The FDA remains wary of a possible risk of blood clot in women taking drospirenone-based birth control pills, such as Bayer's Yasmin and Yaz. Preliminary data from an agency-funded study show a 1.5-fold risk increase for drospirenone compared with other hormonal contraceptives. A panel of medical experts will convene Dec. 8 to tackle the issue.

Related Summaries